Hydroxyethylenediamine rhenium-diphosphonate (Re-188 HEDP) is used to relieve severe pain in prostate cancer bone metastases. Controlling bone pain in patients with multiple bone metastases to improve quality of life is a significant clinical problem. However, its potential and effective treatment with Re-188-HEDP radiopharmaceutical is possible. Rhenium-188 being a gamma emitter can be also used for imaging and the treatment follow-up purposes, and its half-life is 17 hours.
Radiopharmaceutical
theragnostic